These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20632393)

  • 1. Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors.
    Silva-Lima B; Due Theilade-Thomsen M; Carleer J; Vidal JM; Tomasi P; Saint-Raymond A
    Birth Defects Res B Dev Reprod Toxicol; 2010 Dec; 89(6):467-73. PubMed ID: 20632393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
    Duarte DM; Silva-Lima B
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.
    Manolis E; Pons G
    Br J Clin Pharmacol; 2009 Oct; 68(4):493-501. PubMed ID: 19843052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usage of unpublished paediatric data.
    Saint-Raymond A; Pelle B; Zaccaria C; Sennwitz M; Branch S
    Arch Dis Child; 2016 Jan; 101(1):81-4. PubMed ID: 26543071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of juvenile animal studies: a Japanese industry perspective.
    Shimomura K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):266-8. PubMed ID: 21594974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling.
    Tassinari MS; Benson K; Elayan I; Espandiari P; Davis-Bruno K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):261-5. PubMed ID: 21594977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European paediatric legislation: benefits and perspectives.
    Rocchi F; Paolucci P; Ceci A; Rossi P
    Ital J Pediatr; 2010 Aug; 36():56. PubMed ID: 20716337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update of juvenile animal studies in the European Union: What do the numbers say?
    Hurtt ME; Engel S
    Reprod Toxicol; 2015 Aug; 56():105-8. PubMed ID: 25937597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
    Winzenburg G
    Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Better medicines for children: European measures].
    van den Berg H; Taminiau JA
    Ned Tijdschr Geneeskd; 2008 Jul; 152(27):1537-40. PubMed ID: 18681365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who are the PDCO?
    Dempsey EM; Connolly K
    Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of juvenile animal studies to support oncology medicine development in children.
    Duarte DM
    Reprod Toxicol; 2015 Aug; 56():97-104. PubMed ID: 25998230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K; Senn S
    Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical support of pediatric drug development in a global context: an industry perspective.
    Cappon GD
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):269-72. PubMed ID: 21594976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paediatric investigation plans for pain: painfully slow!
    Davies EH; Ollivier CM; Saint Raymond A
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.